AstraZeneca plc (ADR) Upgraded by Societe Generale to Hold (AZN)
AstraZeneca plc (ADR) (NYSE:AZN) was upgraded by research analysts at Societe Generale from a “sell” rating to a “hold” rating in a report released on Friday, TheFlyOnTheWall.com reports.
A number of other firms have also recently commented on AZN. Analysts at Barclays reiterated an “equal weight” rating on shares of AstraZeneca plc (ADR) in a research note on Friday. Separately, analysts at Jefferies Group reiterated a “hold” rating on shares of AstraZeneca plc (ADR) in a research note on Tuesday, April 22nd. Finally, analysts at Deutsche Bank reiterated a “hold” rating on shares of AstraZeneca plc (ADR) in a research note on Tuesday, April 22nd. Five investment analysts have rated the stock with a sell rating, seven have issued a hold rating and seven have issued a buy rating to the company’s stock. AstraZeneca plc (ADR) has a consensus rating of “Hold” and a consensus target price of $66.33.
Shares of AstraZeneca plc (NYSE:AZN) opened at 68.66 on Friday. AstraZeneca plc has a 52-week low of $46.87 and a 52-week high of $70.71. The stock’s 50-day moving average is $65.27 and its 200-day moving average is $60.36. The company has a market cap of $86.580 billion and a price-to-earnings ratio of 42.31.
AstraZeneca plc (ADR) (NYSE:AZN) last posted its quarterly earnings results on Thursday, April 24th. The company reported $1.17 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.23 by $0.06. The company had revenue of $6.42 billion for the quarter, compared to the consensus estimate of $6.32 billion. During the same quarter in the previous year, the company posted $1.41 earnings per share. The company’s revenue for the quarter was up .5% on a year-over-year basis. On average, analysts predict that AstraZeneca plc will post $4.26 earnings per share for the current fiscal year.
AstraZeneca PLC (NYSE:AZN) is a global biopharmaceutical company.
Receive News & Ratings for AstraZeneca plc (ADR) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc (ADR) and related companies with Analyst Ratings Network's FREE daily email newsletter.